All In Biotech

NDA 020201 · Hospira

Dobutamine Hydrochloride In Dextrose 5% In Plastic Container

Dobutamine Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Sep 27, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

80

14 Phase 3, 7 recruiting

FAERS reports

4

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 6, 2026.

INDICATIONS AND USAGE Dobutamine in 5% Dextrose Injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 27, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 400MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 100MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 50MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 200MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dobutamine" as an intervention, any sponsor and status, largest first.

All 80 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthenia1
  • blood pressure increased1
  • burkholderia test positive1
  • device issue1
  • dizziness1
  • drug monitoring procedure not performed1
  • drug therapeutic incompatibility1
  • heart rate increased1
  • product deposit1
  • product packaging confusion1
  • wrong product stored1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20223

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (1 mg/mL) (NDC 0409-0025-10).

  • Current · updated Nov 9, 2026

    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (4 mg/mL) (NDC 0409-1100-10).

  • Current · updated Nov 9, 2026

    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (2 mg/mL) (NDC 0409-0151-10).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,229 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.